---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Effects on other drugs"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Effects on other drugs. Topics: CYP1A2, CYP2C19, and CYP3A4 substrates: probe cocktail study; CYP3A4 activity after 10 days of twice-daily dosing: 4β-hydroxycholesterol marker; P-gp and BCRP substrates: digoxin and rosuvastatin study with the extended-release tablet (PHA022121-C017). 3 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/effects-on-other-drugs"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Effects on other drugs

<a id="heading-2.1.2.9.2"></a>

## 2.1.2.9.2 Effects of Deucrictibant on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

### CYP1A2, CYP2C19, and CYP3A4 substrates: probe cocktail study

> “An open-label, single-sequence cross-over drug-drug interaction study to evaluate the effect of single and multiple oral doses of PHA-022121 on the pharmacokinetics of selective CYP1A2, CYP2C19, and CYP3A4 substrates in healthy subjects”
> “The primary objective of this study is to determine the potential inhibitory/inducing effects of multiple doses of PHA 022121 on the single-dose pharmacokinetics (PK) of a cocktail, containing selective probe substrates of cytochrome P450 (CYP) enzymes (CYP1A2, CYP2C19 and CYP3A4) in healthy adult subjects.”
> “drug cocktail consisting of 50 mg caffeine, 10 mg omeprazole, and 1 mg”

Source: [Onderzoekmetmensen.nl NL-OMON49587](https://www.onderzoekmetmensen.nl/en/node/49587)

<a id="topic-2.1.2.9.2-2"></a>

### CYP3A4 activity after 10 days of twice-daily dosing: 4β-hydroxycholesterol marker

> “Plasma concentrations of 4β-hydroxycholesterol was used as a marker to investigate whether PHA-022121 has an induction or inhibition potential on CYP3A4 activity.”
> “After a dosing period of 10 days with any of the PHA-022121 doses, there were no indications for neither an increase nor a decrease in the CYP3A4 activity, based on plasma 4β hydroxycholesterol concentrations.”

Source: [Groen et al. (2021)](https://ir.pharvaris.com/static-files/f7f8b87d-c488-4611-b3a6-a2275aa94143)

<a id="topic-2.1.2.9.2-3"></a>

### P-gp and BCRP substrates: digoxin and rosuvastatin study with the extended-release tablet (PHA022121-C017)

> “Open-label, drug interaction study to investigate the effect of the extended-release tablet administered once daily on the”
> “pharmacokinetics of the P-gp substrate digoxin and the BCRP”
> “substrate rosuvastatin, administered as a drug cocktail”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

| Register field | Value |
| --- | --- |
| Title | “A Phase I, open-label, fixed sequence drug interaction study in healthy subjects to investigate the effect of a 40 mg deucrictibant tablet administered once daily on the pharmacokinetics of the P-gp substrate digoxin and the BCRP substrate rosuvastatin, administered as a drug cocktail” |
| Protocol | “PHA022121-C017” |
| End of the trial | “21 Oct 2024” |
| Summary of the results | “deferred: adult category 1 trial (mostly phase I), results to be published from” |

Source: [CTIS.eu 2024-514713-35-00](https://ctis.eu/trial/2024-514713-35-00)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
